Merck & Co has agreed to buy Prometheus Biosciences, which specialises in developing treatments for immune-modulated diseases, for $10.8 billion (£8.7 billion) in cash. The main focus of the deal is PRA023 – Prometheus’ antibody directed at tumour necrosis factor-like ligand 1A (TL1A), a protein target associated with intestinal inflammation and fibrosis. PRA023 has had […]
Read More